keyword
MENU ▼
Read by QxMD icon Read
search

Polypill

keyword
https://www.readbyqxmd.com/read/28652091/investigating-therapeutic-usage-of-combined-ticagrelor-and-aspirin-through-solid-state-and-analytical-studies
#1
Hassane Sadou Yayé, Ivo B Rietveld, Maria Barrio, Philippe-Henri Secrétan, Antoine Faucheron, Maher Karoui, Patrick Tilleul, Najet Yagoubi, Bernard Do
The mainstay treatment for patients with acute coronary syndrome is an oral route dual antiplatelet therapy with a P2Y12-receptor antagonist and Aspirin (ASA). To improve patient adherence to such treatments, combination therapies (polypill) are envisioned. Physicochemical solid-state studies have been carried out to develop a preformulation strategy of ASA with the P2Y12-receptor antagonist Ticagrelor (TIC). The investigations were carried out using differential scanning calorimetry, liquid chromatography-high resolution-multistage mass spectrometry (LC-HR-MS(n)) and as complementary techniques Fourier transform infrared measurements and thermogravimetric analysis...
June 23, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28645284/healthcare-expenditure-on-indigenous-and-non-indigenous-australians-at-high-risk-of-cardiovascular-disease
#2
Blake Angell, Tracey-Lea Laba, Tom Lung, Alex Brown, Sandra Eades, Tim Usherwood, David Peiris, Laurent Billot, Graham Hillis, Ruth Webster, Andrew Tonkin, Christopher Reid, Barbara Molanus, Natasha Rafter, Alan Cass, Anushka Patel, Stephen Jan
BACKGROUND: In spite of bearing a heavier burden of death, disease and disability, there is mixed evidence as to whether Indigenous Australians utilise more or less healthcare services than other Australians given their elevated risk level. This study analyses the Medicare expenditure and its predictors in a cohort of Indigenous and non-Indigenous Australians at high risk of cardiovascular disease. METHODS: The healthcare expenditure of participants of the Kanyini Guidelines Adherence with the Polypill (GAP) pragmatic randomised controlled trial was modelled using linear regression methods...
June 23, 2017: International Journal for Equity in Health
https://www.readbyqxmd.com/read/28618914/role-of-the-polypill-for-secondary-prevention-in-ischaemic-heart-disease
#3
José M Castellano, Valentín Fuster, Catriona Jennings, Eva Prescott, Héctor Bueno
In 2011, for the first time in the history of humankind, non-communicable diseases became the leading cause of death worldwide. This change in trend is obviously multifactorial and very complex, as it is the paradoxical result of social, economic and health system growth worldwide. Vaccination and infectious diseases control, changing dietary habits worldwide, sedentary behaviour, globalisation, industrialisation (resulting in a shift from manual to sedentary labour), tobacco and sugary beverage surges in low- and middle-income countries and rapid urbanisation have all played a role in this epidemic transition...
June 2017: European Journal of Preventive Cardiology
https://www.readbyqxmd.com/read/28576674/public-park-spaces-as-a-platform-to-promote-healthy-living-introducing-a-healthpark-concept
#4
REVIEW
Ross Arena, Samantha Bond, Robert O'Neil, Deepika R Laddu, Andrew P Hills, Carl J Lavie, Amy McNeil
The concept of Healthy Living (HL) as a primary medical intervention continues to gain traction, and rightfully so. Being physically active, consuming a nutritious diet, not smoking and maintaining an appropriate body weight constitute the HL polypill, the foundation of HL medicine (HLM). Daily use of the HL polypill, working toward optimal dosages, portends profound health benefits, substantially reducing the risk of chronic disease [i.e., cardiovascular disease (CVD), pulmonary disease, metabolic syndromes, certain cancers, etc...
May 30, 2017: Progress in Cardiovascular Diseases
https://www.readbyqxmd.com/read/28566321/effect-of-intensive-glucose-control-on-microvascular-events-in-people-with-type-2-diabetes
#5
(no author information available yet)
Effect of intensive glucose control on microvascular events in people with type 2 diabetes ● Febrile seizures in children: benefits and risks of prophylactic drug management More on gastric acid suppression and C difficile risk ● What next for the cardiovascular polypill? ● EMA recommends suspension of some generic drugs ● Phototherapy for vitiligo ● WHO targets medication-related errors.
May 31, 2017: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/28566319/what-next-for-the-cardiovascular-polypill
#6
(no author information available yet)
No abstract text is available yet for this article.
June 2017: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/28552061/polypharmacy-in-cardiovascular-medicine-problems-and-promises
#7
Mehran Abolbashari, Tracy E Macaulay, Thomas F Whayne, Debabrata Mukherjee, Sibu Saha
Polypharmacy is now a frequent aspect and reality of current medicine practice, driven by managing multiple comorbidities, especially in older adults. However and unfortunately, polypharmacy can expose patients to adverse drug reactions, and drug-drug or drug-disease interactions. On the other hand, clinicians are often hesitant to add new drugs to complex regimens even when recommended by evidence-based medicine and guidelines. In addition, there is frequently a failure to assess which medications might not be beneficial and may therefore be stopped...
May 28, 2017: Cardiovascular & Hematological Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/28467941/metabolic-surgery-in-a-pill
#8
Alexander D Miras, Carel W le Roux
Bariatric surgery has evolved from a very effective treatment of weight to a treatment of "metabolism" and end-organ damage. Even though surgery was designed with the aim of causing mechanical restriction and calorie malabsorption, mechanistic work in humans and rodents over the last 10 years or so has informed us that this could not be further from the truth. Dietary, pharmacological, and medical device interventions for weight loss and metabolic control have also evolved rapidly only very recently. In this Crosstalk we discuss how close we are to harnessing the clinical efficacy of surgery through a metabolic "polypill...
May 2, 2017: Cell Metabolism
https://www.readbyqxmd.com/read/28448291/the-polypill-in-cardiovascular-prevention-evidence-limitations-and-perspective-position-paper-of-the-european-society-of-hypertension
#9
Antonio Coca, Enrico Agabiti-Rosei, Renata Cifkova, Athanasios J Manolis, Josep Redón, Giuseppe Mancia
: Antihypertensive, lipid lowering, antidiabetic and antiplatelet treatments all substantially reduce the risk of cardiovascular morbid and fatal events. In real life, however, effective implementation of these treatments is rare, and thus their contribution to cardiovascular prevention is much less than it could be, based on research data. This article reviews the pros and cons of cardiovascular prevention by the polypill approach. It is argued that the high prevalence of individuals with a multifactorial risk profile provides a strong rationale for a therapeutic strategy based on the combination in a single tablet of drugs against different risk factors...
August 2017: Journal of Hypertension
https://www.readbyqxmd.com/read/28436727/impact-of-switching-from-different-treatment-regimens-to-a-fixed-dose-combination-pill-polypill-in-patients-with-cardiovascular-disease-or-similarly-high-risk
#10
Melvin Lafeber, Wilko Spiering, Frank Lj Visseren, Diederick E Grobbee, Michiel L Bots, Alice Stanton, Anushka Patel, Dorairaj Prabhakaran, Ruth Webster, Simon Thom, Anthony Rodgers
Aims Cardiovascular fixed-dose combination pills, or polypills, may help address the widespread lack of access and adherence to proven medicines. Initiation of polypill-based care typically entails switching from current separately taken medications. Given the heterogeneity in usual care, there is interest in the impact of polypill treatment across different patterns of prior medication regimen. Methods A total of 2004 participants with established cardiovascular disease or estimated 5-year cardiovascular risk of over 15% were randomised to polypill-based treatment (aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg and either atenolol 50 mg or hydrochlorothiazide 12...
January 1, 2017: European Journal of Preventive Cardiology
https://www.readbyqxmd.com/read/28425033/strengths-and-limitations-of-using-the-polypill-in-cardiovascular-prevention
#11
REVIEW
Ambuj Roy, Nitish Naik, K Srinath Reddy
PURPOSE OF REVIEW: Polypill and its role in cardiovascular disease (CVD) prevention has been extensively discussed and debated since the inception of the concept in 2003. This article reviews the subsequent accumulated research in this area. RECENT FINDINGS: Several short and intermediate to long-term studies with different brands of polypills have analysed the impact of polypill in phase II and III trials. The strengths of polypill that have emerged include better adherence, equivalent or better risk factor control and quality of life among polypill users as compared to usual care...
May 2017: Current Cardiology Reports
https://www.readbyqxmd.com/read/28365096/preventing-bad-and-expensive-things-from-happening-by-taking-the-healthy-living-polypill-everyone-needs-this-medicine
#12
EDITORIAL
Ross Arena, Carl J Lavie
No abstract text is available yet for this article.
March 13, 2017: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/28347977/whatever-happened-to-the-polypill
#13
EDITORIAL
Anthony J Viera
No abstract text is available yet for this article.
March 27, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/28341983/-management-of-different-cardiovascular-risk-factors-with-a%C3%A2-combination-tablet-polypill
#14
REVIEW
P Bramlage, W März, D Westermann, B Weisser, J H Wirtz, U Zeymer, P Baumgart, G van Mark, U Laufs, B K Krämer, T Unger
BACKGROUND: The multifactorial origin of cardiovascular diseases has led to polypharmacy in primary and secondary prophylaxis with evidence-based medications, such as statins, antihypertensive drugs and platelet aggregation inhibitors. The number of prescribed drugs correlates inversely to adherence and can lead to treatment failure. Fixed-dose combination drugs (polypills) could increase the medication adherence of patients, reduce risks and prevent cardiovascular events. METHODS: This review is based on publications that were retrieved from Medline (via PubMed) and The Cochrane Library...
March 24, 2017: Herz
https://www.readbyqxmd.com/read/28320637/polypill-based-therapy-a-promising-therapeutic-strategy
#15
EDITORIAL
Fei Luo, Yuan Guo, Ran Peng, Guiyun Ruan, Xiangping Li
No abstract text is available yet for this article.
March 6, 2017: Heart, Lung & Circulation
https://www.readbyqxmd.com/read/28290999/polypills-an-essential-medicine-for-cardiovascular-disease
#16
EDITORIAL
The Lancet
No abstract text is available yet for this article.
March 11, 2017: Lancet
https://www.readbyqxmd.com/read/28290996/putting-polypills-into-practice-challenges-and-lessons-learned
#17
REVIEW
Ruth Webster, Jose M Castellano, Oyere K Onuma
Regulatory approvals for cardiovascular polypills are increasing rapidly across more than 30 countries. The evidence clearly shows polypills improve adherence and cardiovascular disease risk factors for patients with indications for use of polypill components-ie, those with established cardiovascular disease or at high risk. However, the implementation of polypills into clinical practice has many challenges. The clinical trials literature provides insights into the clinical impact of a polypill strategy, including cost-effectiveness, safety of use, substantial improvement in adherence, and better risk factor control than usual care...
March 11, 2017: Lancet
https://www.readbyqxmd.com/read/28290995/uses-of-polypills-for-cardiovascular-disease-and-evidence-to-date
#18
REVIEW
Mark D Huffman, Denis Xavier, Pablo Perel
Polypills have been approved in more than 30 countries, but worldwide experience with and availability of polypills remain limited, unlike fixed-dose combinations in other diseases such as HIV, tuberculosis, and malaria. In this Series review, we aim to propose a guide for the use of polypills in future research and clinical activities and to synthesise contemporary evidence supporting the use of polypills for prevention of atherosclerosis. Polypill uses can be categorised by population and indication, both of which influence the balance between benefits and risks...
March 11, 2017: Lancet
https://www.readbyqxmd.com/read/28286646/primary-prevention-of-cardiovascular-disease-a-review-of-contemporary-guidance-and-literature
#19
REVIEW
Jack Stewart, Gavin Manmathan, Peter Wilkinson
Cardiovascular disease is a significant and ever-growing problem in the United Kingdom, accounting for nearly one-third of all deaths and leading to significant morbidity. It is also of particular and pressing interest as developing countries experience a change in lifestyle which introduces novel risk factors for cardiovascular disease, leading to a boom in cardiovascular disease risk throughout the developing world. The burden of cardiovascular disease can be ameliorated by careful risk reduction and, as such, primary prevention is an important priority for all developers of health policy...
January 2017: JRSM Cardiovascular Disease
https://www.readbyqxmd.com/read/28263370/fixed-dose-combination-therapy-for-the-prevention-of-atherosclerotic-cardiovascular-diseases
#20
REVIEW
Ehete Bahiru, Angharad N de Cates, Matthew Rb Farr, Morag C Jarvis, Mohan Palla, Karen Rees, Shah Ebrahim, Mark D Huffman
BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and disability worldwide, yet ASCVD risk factor control and secondary prevention rates remain low. A fixed-dose combination of blood pressure- and cholesterol-lowering and antiplatelet treatments into a single pill, or polypill, has been proposed as one strategy to reduce the global burden of ASCVD. OBJECTIVES: To determine the effect of fixed-dose combination therapy on all-cause mortality, fatal and non-fatal ASCVD events, and adverse events...
March 6, 2017: Cochrane Database of Systematic Reviews
keyword
keyword
11650
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"